Microglial production of TNF-α is induced by activated T lymphocytes involvement of VLA-4 and inhibition by interferonβ-1b

Journal of Clinical Investigation

Volumn 100, Issue 3, 1997, Pages 604-612

  Chabot, Sophie ^a   Williams, Gary ^b   Yong, V Wee ^a,c  

^a MCGILL UNIVERSITY   (Canada)

^b BAYER AG   (Germany)

^c UNIVERSITY OF CALGARY   (Canada)

Author keywords

Cytokine; EAE; Glia; Macrophage; Multiple sclerosis

Indexed keywords

BETA1 INTEGRIN; INTERFERON BETA SERINE; RECOMBINANT GAMMA INTERFERON; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; ALLERGIC ENCEPHALOMYELITIS; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DEMYELINATING DISEASE; DOWN REGULATION; HUMAN; HUMAN CELL; MACROPHAGE; MICROGLIA; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

EID: 0030811129     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI119571     Document Type: Article

References (62)

1. Raine, C.S. 1994. The immunology of the multiple sclerosis lesions. Ann. Neurol. 36:S61-S72.
2. Traugott, U., E.L. Reinherz, and C.S. Raine. 1982. Multiple sclerosis: distribution of T cell subsets within active chronic lesions. Science (Wash. DC). 219:308-310.
3. Springer, T.A. 1990. Adhesion receptors of the immune system. Nature (Lond.). 346:425-434.
4. Selmaj, K.W., and C.S. Raine. 1988. Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann. Neurol. 23:339-346.
5. Louis, J.-C., E. Magal, S. Takayama, and S. Varon. 1993. CNTF protection of oligodendrocytes against natural and tumor necrosis factor-induced death. Science (Wash. DC). 259:689-692.
6. D'Souza, S., K. Alinauskas, E. McCrea, C. Goodyer, and J.P. Antel. 1995. Differential susceptibility of human CNS-derived cell populations to TNF-dependent and independent-immune-mediated injury. J. Neurosci. 15:7293-7300.
7. Butt, A.M., and H.G. Jenkins. 1994. Morphological changes in oligodendrocytes in the intact mouse optic nerve following intravitreal injection of tumor necrosis factor. J. Neuroimmunol. 51:27-33.
8. Cannella, B., and C.S. Raine. 1995. The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann. Neurol. 37:424-435.
9. Hofman, P.M., D.R. Hinton, K. Johnson, and J.E. Merrill. 1989. Tumor necrosis factor identified in multiple sclerosis brain. J. Exp. Med. 170:607-612.
10. Selmaj, K., C.S. Raine, B. Cannella, and C.F. Brosnan. 1991. Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions. J. Clin. Invest. 87:949-954.
11. Reickman, N.P., M. Albrecht, B. Kitze, T. Weber, H. Tumani, A. Broocks, W. Luer, A. Helwig, and S. Poser. 1995. Tumor necrosis factor-α messenger RNA expression in patients with relapsing-remitting multiple sclerosis is associated with disease activity. Ann. Neurol. 37:82-88.
12. Ruddle, N.H., C. Bergman, K. McGrath, E. Lingenheld, M. Grunnet, S. Padula, and R. Clark. 1990. An antibody to lymphotoxin prevents transfer of experimental allergic encephalomyelitis. J. Exp. Med. 172:1193-1200.
13. Selmaj, K., W. Papierz, A. Glabinski, and T. Kohno. 1995. Prevention of chronic relapsing experimental autoimmne encephalomyelitis by soluble TNF receptor 1. J. Neuroimmunol. 56:135-141.
14. Selmaj, K.W., and C.S. Raine. 1995. Experimental autoimmune encephalomyelitis: immunotherapy with anti-tumor necrosis factor antibodies and soluble tumor necrosis factor receptors. Neurology. 45:S44-S49.
15. Korner, H., A.L. Goodsall, F.A. Lemckert, B.J. Scallon, J. Ghrayeb, A.L. Ford, and J.D. Sedgwick. 1995. Unimpaired autoreactive T-cell traffic within the central nervous system during tumor necrosis factor receptor-mediated inhibition of experimental autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. USA. 92:11066-11070.
16. Probert, L., K. Akassoglou, M. Pasparakis, G. Kontogeorgos, and G. Kollias. 1995. Spontaneous inflammatory demyelinating disease in transgenic mice showing central nervous system-specific expression of tumor necrosis factor-α. Proc. Natl. Acad. Sci. USA. 92:11294-11298.
17. IFN Multiple Sclerosis Study Group, and UBC MS/MRI Analysis Group. 1995. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology. 45:1277-1285.
18. IFN Multiple Sclerosis Study Group. 1993. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology. 43:655-661.
19. Paty, D.W., D.K.B. Li, the UBC MS/MRI Study Group, and the IFN Multiple Sclerosis Study Group. 1993. Interferon-beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology. 43:662-667.
20. Yu, M., A. Nishiyama, B.D. Trapp, and V.K. Tuohy. 1995. Interferon-β inhibits the progression of relapsing-remitting experimental autoimmune encephalomyelitis. J. Neuroimmunol. 64:91-100.
21. Abreu, S.L. 1985. Interferon in experimental allergic encephalomyelitis (EAE): effects of exogeneous interferon on the antigen-enhanced adoptive transfer of EAE. Int. Arch. Allergy Appl. Immunol. 76:302-307.
22. Brod, S.A., G.D. Marshall, Jr., E.M. Henninger, S. Srinam, M. Khan, and J.S. Wolinsky. 1996. Interferon-β-1b treatment decreases tumor necrosis factor-α and increases interleukin-6 production in multiple sclerosis. Neurology. 46:1633-1638.
23. Renno, T., M. Krakowski, C. Piccirillo, J. Lin, and T. Owens. 1995. TNF-α expression by resident microglia and infiltrating leukocytes in the central nervous system of mice with experimental allergic encephalomyelitis. J. Immunol. 154:944-953.
24. Hickey, W.F., B.L. Hsu, and H. Kimura. 1991. T-Lymphocyte entry into the central nervous system. J. Neurosci. Res. 28:254-260.
25. Williams, K., A. Bar-Or, E. Ulvestad, A. Olivier, J.P. Antel, and V.W. Yong. 1992. Biology of adult human microglia in culture: comparisons with peripheral blood monocytes and astrocytes. J. Neuropath. Exp. Neurol. 51:538-549.
26. Yong, V.W., and J.P. Antel. 1992. Culture of glial cells from human brain biopsies. In Protocols for Neural Cell Culture. S. Fedoroff and A. Richardson, editors. Humana Press, Inc. Totowa, NJ. 81-96.
27. Stuve, O., N.P. Dooley, J.H. Uhm, J.P. Antel, G.S. Francis, G. Williams, and V.W. Yong. 1996. Interferon beta-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloprotenase-9. Ann. Neurol. 40: 853-863.
28. Yong, V.W., R. Moumdjian, F.P. Yong, T.C.G. Ruijs, M.S. Freedman, N. Cashman, and J.P. Antel. 1991. Gamma-interferon promotes proliferation of adult human astrocytes in vitro and reactive gliosis in the adult mouse brain in vivo. Proc. Natl. Acad. Sci. USA. 88:7016-7020.
29. Williams, K.C., N.P. Dooley, E. Ulvestad, A. Waage, M. Blain, V.W. Yong, and J.P. Antel. 1995. Antigen presentation by human fetal astrocytes with the cooperative effect of microglia-derived cytokine, IL-1. J. Neurosci. 15: 1869-1878.
30. Miyake, K., I.L. Weisman, J.S. Greenberger, and P.W. Kincade. 1991. Evidence for a role of the integrin VLA-4 in lympho-hemopoesis. J. Exp. Med. 173:599-607.
31. Miyake, K., K. Medina, K. Ishihara, M. Kimoto, R. Auerbach, and P.W. Kincade. 1991. A VCAM-like adhesion molecule on murine bone marrow stromal cells mediates binding of lymphocyte precursors in culture. J. Cell Biol. 114: 557-565.
32. Balasingam, V., T. Tejada-Berges, E. Wright, R. Bouckova, and V.W. Yong. 1994. Reactive astrogliosis in the neonatal mouse brain and its modulation by cytokines. J. Neurosci. 14:846-856.
33. del Rio-Hortega, P., and W. Penfield. 1927. Cerebral cicatrix. The reaction of neuroglia and microglia to brain wounds. Bull. Johns Hopkins Hosp. 41: 278-303.
34. Stout, R.D., and J. Suttles. 1993. T cell-macrophage cognate interaction in the activation of macrophage effector function by Th2 cells. J. Immunol. 150: 5330-5337.
35. Suttles, J., R.W. Miller, X. Tao, and R.D. Stout. 1994. T cells which do not express membrane tumor necrosis factor-a activate macrophage effector function by cell-contact-dependent signaling of macrophage tumor necrosis factor-α production. Eur. J. Immunol. 24:1736-1742.
36. Yednock, T., C. Cannon, L.C. Fritz, F. Sanchez-Madrid., L. Steinman, and N. Karin. 1992. Prevention of experimental autoimmune encephalomyelitis by antibodies against α4β1 integrin. Nature (Lond.). 356:63-65.
37. Kent, SJ., S.J. Cannon, D.K. Hines, T.A. Yednock, L.C. Fritz, and H.C. Horner. 1995. A monoclonal antibody to alpha-4 integrin suppresses and reverses active experimental allergic encephalomyelitis. J. Neuroimmunol. 58:1-10.
38. Kuchroo, V., C. Martin, J. Greer, S.T. Ju, R.A. Sobel, and M.E. Dorf. 1993. Cytokines and adhesion molecules contribute to the ability of myelin proteolipid protein-specific T cell clones to mediate experimental allergic encephalomyelitis. J. Immunol. 151:4371-4382.
39. Tanaka, M., A. Satom, M. Makino, T. Tabira. 1993. Binding of an SJL T cell clone specific for myelin basic protein to SJL brain microvessel endothelial cells is inhibited by anti-VLA4 or its ligand, anti-vascular cell adhesion molecule 1 antibody. J. Neuroimmunol. 46:253-258.
40. Koyama, Y., Y. Tanaka, K. Saito, M. Abe, K. Nakatsuka, I. Morimoto, P.E. Auron, and S. Eto. 1996. Cross-linking of intercellular adhesion molecule 1 (CD54) induces AP-1 activation and IL-1β transcription. J. Immunol. 157:5097-5103.
41. Soilu-Hanninen, M., A. Salmi, and R. Salonen. 1995. Interferon-β downregulates expression of VLA-4 antigen and antagonizes interferon-γ-induced expression of HLA-DQ on human peripheral blood monocytes. J. Neuroimmunol. 60:99-106.
42. Noronha, A., A. Toscas, and M.A. Jensen. 1993. Interferon β decreases T cell activation and interferon γ production in multiple sclerosis. J. Neuroimmunol. 46:145-154.
43. Rudick, R.A., C.S. Carpenter, D.L Cookfair, V.K. Tuohy, and R.M. Ransohoff. 1996. In vitro and in vivo inhibition of mitogen-driven T-cell activation by recombinant interferon beta. Neurology. 43: 2080-2087.
44. Weinstock-Guttman, B., R.M. Ransohoff, R.P. Kindel, and R.A. Rudick. 1995. The interferons: biological effects, mechanisms of action, and use in multiple sclerosis. Ann. Neurol. 37:7-15.
45. Sedgwick, J., S. Brostoff, and D. Mason. 1987. Experimental allergic encephalomyelitis in the absence of a classical delayed type hypersensitivity reaction: severe paralytic disease correlates with the presence of interleukin-2 receptor-positive cells infiltrating the central nervous system. J. Exp. Med. 165: 1058-1075.
46. 14C-labeled cells during acute, chronic, and relapsing experimental allergic encephalomyelitts. Lab. Invest. 63:253-258.
47. Cross, A.H., T. O'Mara, and C.S. Raine. 1993. Chronologic localization of myelin-reactive cells in the lesions of relapsing EAE. Neurology. 43:1028-1033.
48. Oksaranta, O., S. Tarvonen, J. Ilonen, K. Poikonen, M. Reunanen, M. Panelius, and R. Salonen. 1995. Influx of nonactivated T lymphocytes into the cerebrospinal fluid during relapse of multiple sclerosis. Ann. Neurol. 38:465-468.
49. Meda, L., M. Cassatella, G. Szendrei, L. Otvos, Jr., P. Baron, M. Villalba, D. Ferrari, and F. Rossi. 1995. Activation of microglial cells by β-amyloid protein and interferon-γ. Nature (Lond.). 374:647-650.
50. Becher, B., V. Dodelet, V. Fedorowicz, and J.P. Antel. 1996. Soluble tumor necrosis factor receptor inhibits interleukin-12 production by stimulated human adult microglia cells in vitro. J. Clin. Invest. 98:1539-1543.
51. Stout, R.D., J. Suttles, J. Xu, I.S. Grewal, and R.A. Flavell. 1996. Impaired T cell-mediated macrophage activation in CD40 ligand-deficient mice. J. Immunol. 156:8-11.
52. + T cell responses. Immunol. Today. 17:410-414.
53. Tanaka, M., A. Satom, M. Makino, and T. Tabira. 1993. Binding of an SJL T cell clone specific for myetin basic protein to SJL brain microvessel endothelial cells is inhibited by anti-VLA-4 or its ligand, anti-vascular cell adhesion molecule-1 antibody. J. Neuroimmunol. 46:253-258.
54. + T cells is required for their entry into brian parenchyma. J. Exp. Med. 177:57-68.
55. Fernandez, O., A. Antiquedad, T. Arbizu, A. Capdevila, P. de Castro, J. Correa de Sa, J. Garcia-Merino, G. Izquierdo, A. Magalhaes, X. Montalban, and J. Zarranz. 1995. Treatment of relapsing-remitting multiple sclerosis with natural interferon beta: a multicenter, randomized clinial trial. Multiple Sclerosis. 1:S67-S69.
56. Jacobs, L., D. Cookfair, R. Rudick, R. Herndon, J. Riehen, A. Salazar, J. Fischer, D. Goodkin, C. Granger, J. Simon, et al. 1996. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann. Neurol. 39:285-294.
57. Lublin, F.D., J.N. Whitaker, B.H. Eidelman, A.E. Miller, B.G.W. Arnason, and J.S. Burks. 1996. Management of patients receiving interferon beta-1b for multiple sclerosis: report of a consensus conference. Neurology. 46:12-18.
58. Panitch, H.S., and C.T. Bever, Jr. 1993. Clinical trials of interferons in multiple sclerosis. What have we learned? J. Neuroimmunol. 46:155-164.
59. Noronha, A., A. Toscas, and M.A. Jensen. 1995. Contrasting effects of alpha, beta and gamma interferons on nonspecific suppressor function in multiple sclerosis. Ann. Neurol. 37:7-15.
60. O'Gorman, M.R.G., J. Oger, and L.F. Kastrukoff. 1987. Reduction of immunoglobulin G secretion in vitro following long term lymphoblastoid interferon (Wellferon) treatment in multiple sclerosis patients. Clin. Exp. Immunol. 67:66-67.
61. Hynes, R.O. 1992. Integrins: versatility, modulation, and signaling in cell adhesion. Cell. 69:11-25.
62. Vassalli, P. 1992. The pathophysiology of tumor necrosis factors. Annu. Rev. Immunol. 10:411-452.